We are live on ! Find out more
INM icon

InMed Pharmaceuticals
INM

13 hedge funds and large institutions have $2.99M invested in InMed Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more capital invested

Capital invested by funds: $1.55M → $2.99M (+$1.44M)

0.01% more ownership

Funds ownership: 0.01% → 0.02% (+0.01%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

13% less funds holding

Funds holding: 15 → 13 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
13
Holders Change
-2
Holders Change %
-13.33%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$2.03M
2
PCM
Penserra Capital Management
California
+$61.9K
3
UBS Group
UBS Group
Switzerland
+$3.1K

Top Sellers

Rank Fund Capital Flow
1
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$531K
2
Bank of America
Bank of America
North Carolina
-$53K
3
JP Morgan Chase
JP Morgan Chase
New York
-$36K
4
Morgan Stanley
Morgan Stanley
New York
-$35.6K
5
Citadel Advisors
Citadel Advisors
Florida
-$4.64K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$2.83M +$2.03M +1,310 +279%
Citadel Advisors
2
Citadel Advisors
Florida
$49K -$4.64K -3 -9%
PCM
3
Penserra Capital Management
California
$49K +$61.9K +40 New
Creative Planning
4
Creative Planning
Kansas
$34K – – –
UBS Group
5
UBS Group
Switzerland
$7K +$3.1K +2 +100%
PNC Financial Services Group
6
PNC Financial Services Group
Pennsylvania
$6K – – –
Osaic Holdings
7
Osaic Holdings
Arizona
$4K – – –
Morgan Stanley
8
Morgan Stanley
New York
$2K -$35.6K -23 -92%
AWM
9
AllSquare Wealth Management
New York
$2K – – –
RFA
10
Reilly Financial Advisors
California
$2K – – –
FDCDDQ
11
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.63K – – –
FF
12
FourThought Financial
Florida
$1K – – –
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$1K – – –
Hudson Bay Capital Management
14
Hudson Bay Capital Management
Connecticut
– -$531K -322 Closed
Bank of America
15
Bank of America
North Carolina
– -$53K -32 Closed
JP Morgan Chase
16
JP Morgan Chase
New York
– -$36K -15 Closed
Bank of Montreal
17
Bank of Montreal
Ontario, Canada
– -$1K – –

INM Hedge Fund Activity: Q2 2021 in Review

13 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q2 2021, worth a combined $2.99M — up 93% from $1.55M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of INM and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.

The largest buyer was Armistice Capital, adding an estimated $2.03M. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $531K sold.

  • 13 institutional investors held InMed Pharmaceuticals (INM) as of Q2 2021, down from 15 in Q1 2021.
  • Funds reported $2.99M of InMed Pharmaceuticals stock for Q2 2021, up 93% quarter-over-quarter.
  • 1 fund opened new InMed Pharmaceuticals positions in Q2 2021 and 3 closed out, a net change of -2 holders.
  • The largest InMed Pharmaceuticals buyer in Q2 2021 was Armistice Capital, an estimated $2.03M added.
  • The largest InMed Pharmaceuticals seller in Q2 2021 was Hudson Bay Capital Management, an estimated $531K sold.

Based on aggregated 13F filings for Q2 2021.